AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Aug 05, 2021

New science, technology, and dedication improve dermatopathology

Dedication and attention to detail by dermatologists enhance the effectiveness of new developments.


Alina G. Bridges, DO, FAAD
Alina G. Bridges, DO, FAAD

New evidence and approaches are bringing important changes to dermatopathology. These include screening for genetic syndromes using immunohistochemistry, molecular testing, new immunochemistry stains, and new considerations in managing atypical nevi, to list a few changes. What hasn’t changed is the need for clinicians to provide complete biopsy specimens, photos and images, and relevant clinical information.

“We want to be sure we are looking at adequate specimens, the entire lesion,” said Alina G. Bridges, DO, FAAD, director of immunodermatology at the Richfield Laboratory of Dermatopathology. “We need to know that half the lesion isn’t still on the patient and that remnant has melanoma when all we see is a little atypia.”

Dr. Bridges will review the latest developments during “Game Changers in Dermatopathology” (U019) Saturday morning. It takes more than new science and technology to change the game of dermatopathology, she said. It also takes dedication and attention to detail by dermatologists.

Patients with a history of dysplastic nevi are at increased risk for developing melanomas, and the melanomas are more likely to develop at a new site, she said. Current guidelines suggest that patients with moderately dysplastic nevi should be followed for later melanomas. But a dermatopathologic finding of moderate dysplasia in a nevus is only as good as the submitted specimen that was assessed.

“If there is any concern that the patient has a highly suspicious pigmented lesion, then the lesion should be sampled as an excisional biopsy with 1-3 mm clear clinical margins rather than a partial biopsy,” Dr. Bridges advised.

Immunohistochemical staining is another important issue. Stains can be expensive, and a barrier to care for patients who are uninsured or have high deductibles. She suggested ordering stains only if there is a need to improve diagnostic capabilities, help with prognosis, and guide therapy.

Some lesions are more suspicious than others. Staining could be helpful for patients with sebaceous adenomas or sebaceous carcinomas and sometimes reticulated acanthomas with sebaceous differentiation. These neoplasms can be associated with Muir-Torre syndrome, a variant of hereditary nonpolyposis colorectal cancer. If immunochemical staining reveals defective DNA mismatch repair proteins, the patient can be referred to medical genetics for further evaluation.

She said dermatopathologists are excited about a new stain called PRAME, preferentially expressed antigen in melanoma, which can help distinguish melanoma from a benign nevus. But like many stains, PRAME is not foolproof. It cannot always identify desmoplastic melanoma, which has the lowest positivity of all melanoma subtypes.

“Sometimes a regular nevus is positive and sometimes an unequivocal melanoma is negative,” Dr. Bridges cautioned. “Many people are bringing it on board, but it is not a replacement for other melanocytic markers.”

There is also a novel immunostain for the Merkel cell polyomavirus. A positive stain is associated with a better prognosis. Loss of BAP1 nuclear immunohistochemistry staining can identify a BAPoma or BAP1 inactivated melanocytic tumor, which can be associated with a BRAFV600E mutation.

Molecular testing is becoming similarly important, Dr. Bridges said. Testing is currently recommended when a diagnosis of melanoma is in question and in cases of indeterminant atypical melanocytic neoplasms.

“Molecular testing adds to the cost, but is almost essential for diagnosis, prognosis, and therapy in these difficult melanocytic neoplasms,” she said. “If, based on testing, for example, an atypical Spitz tumor chromosomal aberrations like melanoma, then we diagnose and manage the lesion as melanoma, although it often has a better prognosis. This is significant because atypical Spitz nevi and tumors can occur in younger patients.”


 

Interesting Stories
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
More in Summer Meeting 2021
Peter Lio, MD, FAAD
Summer Meeting 2021
The secrets of minimizing pain
Aug 11, 2021
Lawrence S. Chan, MD, FAAD
Summer Meeting 2021
Biomedical advancements impact dermatologic diagnosis and treatment
Aug 11, 2021
Todd Schlesinger, MD, FAAD
Summer Meeting 2021
Update on managing advanced skin cancer
Aug 11, 2021
Hensin Tsao, MD, PhD, FAAD
Summer Meeting 2021
HPV vax, psoriasis biologics, and caregiver quality of life highlight FiRST session
Aug 11, 2021
07e
Summer Meeting 2021
Summer Meeting packed a welcome punch
Aug 11, 2021
Mario E. Lacouture, MD, FAAD
Summer Meeting 2021
Oncodermatology takes the stage at Fox Lectureship
Aug 06, 2021
Julie Gerberding, MD, MPH
Summer Meeting 2021
COVID-19: A “predictable surprise”
Aug 06, 2021
Aimee Payne, MD, PhD, FAAD
Summer Meeting 2021
Frost Lectureship traces mPV treatment’s path from lab to clinical trial
Aug 06, 2021
2020 Gold Medal Presentation | Professor R. Rox Anderson, MD (left), Lancer Endowed Chair in Dermatology, Harvard Medical School and Director, Wellman Center for Photomedicine at Mass. General Hospital. 2021 Gold Medal Presentation | Dirk Michael Elston, MD, FAAD (right), Medical University of South Carolina.
Summer Meeting 2021
Two physicians honored with AAD Gold Medal awards
Aug 05, 2021
Sm21 F008 1526e
Summer Meeting 2021
How to have mindful, effective conversations with patients
Aug 05, 2021
Sergey Rekhtman, MD, FAAD, PharmD, MPH, and Sheila Shaigany, MD, FAAD
Summer Meeting 2021
Lessons from COVID-19’s cutaneous manifestations
Aug 05, 2021
Charlene Lam, MD, MPH, FAAD
Summer Meeting 2021
“Uninvite” disaster by planning
Aug 05, 2021
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.